The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
|ClinicalTrials.gov Identifier: NCT00001074|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : July 29, 2013
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Hydroxyurea Drug: Didanosine||Phase 1|
Current antiviral therapies for HIV-1 are limited by a few choices, and the lack of sustained clinical benefit from the drugs. The mechanisms that account for the lack of prolonged inhibition of viral replication by these agents are not fully understood. The activity of RT inhibitors might be potentiated by inhibiting host cellular enzymes essential for efficient HIV reverse transcription. Based on this information, comparisons of the antiviral effects of ddI monotherapy and hydroxyurea plus ddI, with the cellular enzyme ribonucleotide reductase as a potential target, should be done.
This is a 24-week study, with two 12-week treatment periods. Patients are randomized to one of five treatment arms based upon a patient's history of antiretroviral therapy (naive vs. experienced). The five treatment arms are:
- ddI plus hydroxyurea placebo.
- hydroxyurea (lower dose) plus ddI placebo for 4 weeks; then hydroxyurea (higher dose) plus ddI.
- hydroxyurea (higher dose) plus ddI placebo for 4 weeks; then hydroxyurea (higher dose) plus ddI.
- hydroxyurea (lower dose) plus ddI.
- hydroxyurea (higher dose) plus ddI. After the completion of week 12, patients on combination therapy remain on their current therapy and patients on ddI plus placebo have hydroxyurea replace the placebo at 1 of 2 assigned doses (1:1 randomization). AS PER AMENDMENT 5/5/97: If after the 24-week treatment period, a patient has an RNA level less than or equal to 5,000 copies/ml or less than 20,000 copies/ml with a greater than 1 log10 decline from baseline, she has the option to continue therapy open-label ddI plus hydroxyurea for an additional 24 weeks.
AS PER AMENDMENT 10/1/97: Accrual to the arms involving hydroxyurea alone has been closed. Patients are randomized to one of the three treatment arms, as follows:
- hydroxyurea placebo plus ddI.
- hydroxyurea (lower dose) plus ddI.
- hydroxyurea (higher dose) plus ddI.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||140 participants|
|Official Title:||A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection|
|Study Completion Date :||January 2000|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001074
|United States, California|
|Univ of California / San Diego Treatment Ctr|
|San Diego, California, United States, 921036325|
|Stanford at Kaiser / Kaiser Permanente Med Ctr|
|San Francisco, California, United States, 94115|
|Stanford Univ Med Ctr|
|Stanford, California, United States, 943055107|
|Harbor UCLA Med Ctr|
|Torrance, California, United States, 90502|
|United States, Colorado|
|Univ of Colorado Health Sciences Ctr|
|Denver, Colorado, United States, 80262|
|United States, Maryland|
|Johns Hopkins Hosp|
|Baltimore, Maryland, United States, 21287|
|United States, New York|
|Beth Israel Med Ctr|
|New York, New York, United States, 10003|
|Bellevue Hosp / New York Univ Med Ctr|
|New York, New York, United States, 10016|
|Mount Sinai Med Ctr|
|New York, New York, United States, 10029|
|United States, North Carolina|
|Univ of North Carolina|
|Chapel Hill, North Carolina, United States, 275997215|
|Duke Univ Med Ctr|
|Durham, North Carolina, United States, 27710|
|United States, Ohio|
|Univ of Cincinnati|
|Cincinnati, Ohio, United States, 452670405|
|Case Western Reserve Univ|
|Cleveland, Ohio, United States, 44106|
|MetroHealth Med Ctr|
|Cleveland, Ohio, United States, 441091998|
|United States, Pennsylvania|
|Univ of Pennsylvania at Philadelphia|
|Philadelphia, Pennsylvania, United States, 19104|
|Thomas Jefferson Univ Hosp|
|Philadelphia, Pennsylvania, United States, 191075098|
|United States, South Carolina|
|West Columbia, South Carolina, United States, 29169|
|United States, Washington|
|Univ of Washington|
|Seattle, Washington, United States, 981224304|
|Study Chair:||Ian Frank, MD||Division of Infectious Diseases, University of Pennsylvania|
|Study Chair:||Joseph Eron, MD||University of North Carolina|